AKTX vs AMCR · $17.2M cap vs P/E 18, rev $23.51B
Akari Therapeutics PLC (AKTX) versus Amcor PLC (AMCR) — a side-by-side from cached financials, not a winner call.
Akari Therapeutics PLC (AKTX) is a biotechnology company listed on US.
Amcor PLC (AMCR) is a packaging & containers company listed on US.
AKTX does not have a complete income-statement cache yet.
Latest reported AMCR revenue for 2026-06-30 was $23.51B. Net income was $1.11B. Revenue was up 362.5% from 2025-06-30 to 2026-06-30. AMCR currently screens at market cap $22.52B and trailing P/E 17.6.
AKTX currently screens at market cap $17.2M. AMCR currently screens at market cap $22.52B and trailing P/E 17.6.
Not investment advice. Open the AKTX and AMCR stock pages for the full models.
Not investment advice.